Seattle venture capital firm Frazier Healthcare has raised $281.8 million for its seventh fund, according to a SEC filing today. The company, which is targeting $300 million, has received the funds from 20 investors. Those funds include three percent from the “general partner,” according to the filing.
The latest filing indicates that the firm — founded by former Immunex executive Alan Frazier in 1991— has raised $82.5 million.
Last summer, the firm indicated in a filing that it was looking to raise up to $400 million. It is currently investing out of a $600 million fund formed in 2008.
A national firm, Frazier’s portfolio includes Achaogen, Atterocor, Portola Pharmaceuticals and other firms. It has been relatively quiet on the Seattle investment front in recent months, but past investments have included ZymoGenetics, Calistoga Pharmaceuticals and Calypso Medical.
Citing SEC regulations, a spokeswoman for Frazier declined to comment.
